CAS 282526-98-1 API Raw Material Metformin Hcl Powder

CAS 282526-98-1 API raw material metformin hcl powder

Whatsapp:+86 15202961574

Metformin is a biguanide oral hypoglycemic drug that can promote the uptake of glucose in adipose tissue, increase the anaerobic glycolysis of muscle tissue, increase the use of glucose, reduce insulin resistance, reduce glucose absorption through the digestive tract, and reduce blood glucose. It is used in adults with non-insulin-dependent glucose Chemicalbook urine disease and partially dependent diabetes mellitus For the majority of juvenile diabetes patients with lean diabetes who have failed sulfonylureas, this product can also reduce blood glucose after use. Clinical use can be combined with sulfonylureas or insulin to enhance its hypoglycemic effect. Obese patients can also lose weight with this product

How does metformin become the most promising anti-aging drug?

Metformin was first found in a kind of forage called Galega.

In 1918, scientists extracted guanidine from goat beans for the first time and proved that guanidine can reduce blood sugar. In 1929, Irish scientists synthesized metformin with high efficiency and low toxicity.

The hypoglycemic mechanism of metformin is relatively complex, which has not been fully understood until now. The main process is to inhibit the output of liver glycogen and promote the uptake of glucose by peripheral tissues (such as muscles, fats and organs). Both of these ways regulate the body's own metabolic capacity, rather than directly acting on the pancreatic islets to stimulate insulin secretion, which can reduce insulin resistance. Metformin also reduces the absorption of sugar in the gut.

In recent years, metformin is not limited to the treatment of diabetes. In addition to lowering blood sugar, more and more studies have found that metformin can also improve lipid metabolism, lose weight, reduce the incidence of cardiovascular complications, and even delay the aging process and prolong life. The mechanisms of these actions are also complex. Currently metformin is only approved by the FDA for the treatment of type 2 diabetes, but it is often used off-label for prediabetes, PCOS (polycystic ovary syndrome), gestational diabetes, and weight gain associated with antipsychotics

The main evidence for whether metformin can prolong life is a 2014 retrospective study published in the journal Diabetes, Obesity and Metabolism by researchers at Cardiff University. In the retrospective study of 180,000 people, about 90,000 of whom were diabetic, the average observation period was 2.8 years. Studies have shown that long-term use of metformin can significantly extend the lives of people with type 2 diabetes, who are likely to live longer than non-diabetics, for whom the drug also has health benefits.

The COA of Metformin powder: